Gilead Sciences Inc. said that its Quad regimen for treating HIV infection met its primary objective in a Phase II study, fueling hopes that the combination pill could diversify the company's pipeline as its blockbuster HIV drugs face a looming patent cliff. (BioWorld Today)

Keryx, FDA Agree on Design of Phase III Zerenex Trials

Jan. 6, 2010

By Catherine Hollingsworth

Anesiva to Cease Operations After Merger with Arcion Dies

Jan. 5, 2010

By Catherine Hollingsworth

Tengion Joins Biotech IPO Parade Seeking Up to $40M

Dec. 28, 2009

By Catherine Hollingsworth

PTC Gets $50M to Launch Ataluren, Further Studies

Dec. 23, 2009

By Catherine Hollingsworth

PTC Therapeutics Inc. has completed a $50 million financing, the proceeds for which will be used to prepare for the anticipated launch of the drug in Duchenne's muscular dystrophy in the first half of 2011. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.